OXiGENE Reports Positive Preclinical Ocular Penetration Data with Topical Formulation of ZYBRESTAT(TM) for Ophthalmology
December 31, 2007 09:01 ET
|
Oxigene, Inc.
OXiGENE Reports Positive Preclinical Ocular Penetration Data with Topical
Formulation of ZYBRESTAT(TM) for Ophthalmology
Key Feasibility Hurdle Overcome in Topical Ophthalmology Program
WALTHAM,...
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
December 31, 2007 09:00 ET
|
Oxigene, Inc.
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in
Platinum-Resistant Ovarian Cancer
Meets Pre-specified Primary Efficacy Endpoint in Stage 1 of Simon Two-Stage
Study
WALTHAM,...
OXiGENE to Report on ZYBRESTAT(TM) Pivotal Trial Progress in Presentation to Investors in Sweden
December 11, 2007 00:01 ET
|
Oxigene, Inc.
OXiGENE to Report on ZYBRESTAT(TM) Pivotal Trial Progress in Presentation to
Investors in Sweden
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 11, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN,...
OXiGENE's ZYBRESTAT(TM) Reported to Have Anti-Leukemic Effects in Preclinical Studies Published in Blood
November 28, 2007 09:10 ET
|
Oxigene, Inc.
OXiGENE's ZYBRESTAT(TM) Reported to Have Anti-Leukemic Effects in Preclinical
Studies Published in Blood
Results Suggest Broader Clinical Potential for Novel Anti-Cancer Drug Candidate
WALTHAM,...
OXiGENE To Present at LAZARD Healthcare Conference on November 28
November 26, 2007 11:01 ET
|
Oxigene, Inc.
OXiGENE To Present at LAZARD Healthcare Conference on November 28
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 26, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a...
OXiGENE REPORTS THIRD QUARTER 2007 RESULTS, CLINICAL AND CORPORATE HIGHLIGHTS
November 01, 2007 09:02 ET
|
Oxigene, Inc.
OXiGENE REPORTS THIRD QUARTER 2007 RESULTS, CLINICAL AND CORPORATE HIGHLIGHTS
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 1, 2007--OXiGENE, Inc.
(NASDAQ: OXGN, XSSE: OXGN), a clinical-stage...
OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published in Peer-Review Journal
October 24, 2007 15:30 ET
|
Oxigene, Inc.
OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published
in Peer-Review Journal
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 24, 2007--Regulatory News:
OXiGENE, Inc....
OXiGENE Reports Positive Interim Results from Phase Ib ZYBRESTAT(TM) - Bevacizumab Combination Study in Advanced Solid Tumors
October 05, 2007 07:47 ET
|
Oxigene, Inc.
OXiGENE Reports Positive Interim Results from Phase Ib ZYBRESTAT(TM) -
Bevacizumab Combination Study in Advanced Solid Tumors
Combination Regimen Appears Safe and Well-Tolerated with Early Evidence...
OXiGENE To Present at BIO Investor Forum on October 11
October 04, 2007 17:25 ET
|
Oxigene, Inc.
OXiGENE To Present at BIO Investor Forum on October 11
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 4, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a...
OXiGENE To Present at UBS Global Life Sciences Conference in NYC September 27
September 19, 2007 09:23 ET
|
Oxigene, Inc.
OXiGENE To Present at UBS Global Life Sciences Conference in NYC September 27
Presentation Available via Webcast
WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 19, 2007--Regulatory News:
OXiGENE,...